Represented Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) in connection with an At Market Issuance Sales Agreement with FBR Capital Markets & Co., MLV & Co. LLC, and H.C. Wainwright & Co., LLC, in connection with the offering, issuance and sale of up to $150 million of Spectrum’s Common Stock under the previously-filed shelf registration statement on Form S-3, for the offering of up to $250 million of common stock, preferred stock, debt securities, warrants for debt or equity securities and units (the “Shelf Registration Statement”).
Represented JLJH Management, LLC in connection with the private offering of Limited Liability Company Units to over 40 existing and new investors, resulting in total gross proceeds of $2 million.
Represented BarioSurg, Inc. in its merger of equals with EnteroMedics Inc., a publicly traded Delaware corporation (NASDAQ CM:ETRM), whereby Enteromedics acquired all of the equity of BarioSurg in exchange for the issuance of 1,380,684 shares of Enteromedics Common Stock, 1,000,181 shares of Enteromedics newly created Convertible Preferred Stock (convertible into approximately five million shares of Enteromedics Common Stock upon approval of Enteromedics’ stockholders) and $2 million in cash (less transaction expenses).
Represented Wicked Weed Brewing, one of the fastest-growing craft breweries in Asheville, North Carolina, in connection with its sale to Anheuser-Busch. Wicked Weed Brewing will join The High End, a business unit of Anheuser-Busch that provides unique craft and European import brands. Read the Press Release.
On October 5, 2016, Stradling client VolitionRx Limited (NYSE MKT: VNRX) completed an underwritten public offering of 2.25 million shares of Common Stock, followed by the October 21, 2016 closing of an additional 234,404 shares sold pursuant to the exercise of the underwriters’ overallotment option, at a public offering price of $5.00 per share, for total gross proceeds of approximately $12.4 million. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, production commercialization, working capital and other general corporate purposes.
Represented VolitionRx Limited (NYSE MKT: VNRX) in its underwritten public offering of 3,769,231 shares of Common Stock, including 565,384 shares sold pursuant to the exercise in full of the underwriters’ overallotment option, at a public offering price of $3.25 per share for net proceeds of approximately $12.8 million. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, production commercialization, working capital and other general corporate purposes.
Represented TherOx, Inc. in its second subsequent closing of its Series A Preferred Stock financing. In this closing, TherOx issued and sold shares of its Series A Preferred Stock to investors, including Zoll Medical Corporation.
Represented Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in the execution of license and supply agreements in connection with its strategic partnership with Servier Canada, Inc. for the out-license of commercialization rights to ZEVALIN®, FOLOTYN®, BELEODAQ®, and MARQIBO® in Canada.
Advised Spectrum Pharmaceuticals Cayman, L.P., a wholly-owned subsidiary of Stradling client Spectrum Pharmaceuticals, Inc., on a license and asset purchase agreement with Mundipharma International Corporation Limited regarding the exclusive commercialization rights to ZEVALIN in Asia, excluding India and Greater China, Australia/New Zealand, Africa, the Middle East, and Latin America (including the Caribbean). Pursuant to the terms of the transaction, Spectrum Pharmaceuticals Cayman will receive $20 million, comprised of an upfront payment of $15 million plus $5 million in profits on the initial ZEVALIN supply.
On October 13, 2015, the Members of MPJ Management, LLC, doing business as Saint Archer Brewing Co. of San Diego, a client of Stradling, completed its sale of majority interest to MillerCoors LLC for an undisclosed price.
Stradling client TherOx, Inc. completed the first closing of its sale of new Series A Preferred Stock to existing and new investors, including lead investor DAG Ventures, and concurrently recapitalized existing Bridge Notes, Preferred Stock and Common Stock, for a total purchase price of approximately $16.8 million.